Research Analysts Offer Predictions for TARS Q2 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Analysts at William Blair decreased their Q2 2025 earnings estimates for Tarsus Pharmaceuticals in a report issued on Monday, July 14th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings per share of ($0.48) for the quarter, down from their prior estimate of ($0.43). The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals' FY2025 earnings at ($1.43) EPS.

A number of other equities research analysts have also recently commented on the company. HC Wainwright raised Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price on the stock in a research note on Tuesday, May 27th. Guggenheim raised their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They issued an "outperform" rating and a $75.00 target price on the stock. The Goldman Sachs Group increased their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Finally, Wall Street Zen lowered Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $66.67.

Tarsus Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ:TARS traded up $0.97 during midday trading on Wednesday, reaching $41.55. The company's stock had a trading volume of 476,901 shares, compared to its average volume of 685,271. The company has a quick ratio of 5.54, a current ratio of 5.57 and a debt-to-equity ratio of 0.21. The firm has a 50 day moving average of $42.12 and a 200-day moving average of $46.83. Tarsus Pharmaceuticals has a 12-month low of $20.08 and a 12-month high of $57.28. The firm has a market capitalization of $1.75 billion, a P/E ratio of -15.22 and a beta of 0.80.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals during the fourth quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at $44,000. Amalgamated Bank increased its holdings in Tarsus Pharmaceuticals by 30.1% in the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock valued at $65,000 after buying an additional 295 shares in the last quarter. Quarry LP purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $166,000. Finally, AlphaQuest LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the 1st quarter valued at about $189,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.